Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8WW27
UPID:
ABEC4_HUMAN
Alternative names:
Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 4
Alternative UPACC:
Q8WW27; Q8N7F6
Background:
The Putative C->U-editing enzyme APOBEC-4, also known as Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 4, represents a unique class of enzymes with a speculated role in RNA editing, specifically in the conversion of cytosine to uracil. Its exact physiological substrates and mechanisms of action remain to be fully elucidated, making it a subject of significant scientific interest.
Therapeutic significance:
Understanding the role of Putative C->U-editing enzyme APOBEC-4 could open doors to potential therapeutic strategies. Its involvement in RNA editing processes suggests a possible impact on gene expression regulation, which could be pivotal in treating genetic disorders.